Newark, DE, United States
Newark, DE, United States

Time filter

Source Type

Knabel S.J.,Pennsylvania State University | Reimer A.,Public Health Agency of Canada | Verghese B.,Pennsylvania State University | Verghese B.,Accugenix Inc. | And 12 more authors.
Journal of Clinical Microbiology | Year: 2012

Human listeriosis outbreaks in Canada have been predominantly caused by serotype 1/2a isolates with highly similar pulsedfield gel electrophoresis (PFGE) patterns. Multilocus sequence typing (MLST) and multi-virulence-locus sequence typing (MVLST) each identified a diverse population of Listeria monocytogenes isolates, and within that, both methods had congruent subtypes that substantiated a predominant clone (clonal complex 8; virulence type 59; proposed epidemic clone 5 [ECV]) that has been causing human illness across Canada for more than 2 decades. Copyright © 2012, American Society for Microbiology. All Rights Reserved.


Verghese B.,Pennsylvania State University | Lok M.,Pennsylvania State University | Lok M.,Strategic Diagnostics Inc. | Wen J.,Pennsylvania State University | And 4 more authors.
Applied and Environmental Microbiology | Year: 2011

Different strains of Listeria monocytogenes are well known to persist in individual food processing plants and to contaminate foods for many years; however, the specific genotypic and phenotypic mechanisms responsible for persistence of these unique strains remain largely unknown. Based on sequences in comK prophage junction fragments, different strains of epidemic clones (ECs), which included ECII, ECIII, and ECV, were identified and shown to be specific to individual meat and poultry processing plants. The comK prophage-containing strains showed significantly higher cell densities after incubation at 30°C for 48 h on meat and poultry food-conditioning films than did strains lacking the comK prophage (P < 0.05). Overall, the type of strain, the type of conditioning film, and the interaction between the two were all highly significant (P < 0.001). Recombination analysis indicated that the comK prophage junction fragments in these strains had evolved due to extensive recombination. Based on the results of the present study, we propose a novel model in which the concept of defective comK prophage was replaced with the rapid adaptation island (RAI). Genes within the RAI were recharacterized as "adaptons,"as these genes may allow L. monocytogenes to rapidly adapt to different food processing facilities and foods. If confirmed, the model presented would help explain Listeria's rapid niche adaptation, biofilm formation, persistence, and subsequent transmission to foods. Also, comK prophage junction fragment sequences may permit accurate tracking of persistent strains back to and within individual food processing operations and thus allow the design of more effective intervention strategies to reduce contamination and enhance food safety. © 2011, American Society for Microbiology. All Rights Reserved.


Grindel B.J.,Rice University | Martinez J.R.,Rice University | Pennington C.L.,Rice University | Muldoon M.,Strategic Diagnostics Inc | And 3 more authors.
Matrix Biology | Year: 2014

Perlecan/HSPG2, a large heparan sulfate (HS) proteoglycan, normally is expressed in the basement membrane (BM) underlying epithelial and endothelial cells. During prostate cancer (PCa) cell invasion, a variety of proteolytic enzymes are expressed that digest BM components including perlecan. An enzyme upregulated in invasive PCa cells, matrilysin/matrix metalloproteinase-7 (MMP-7), was examined as a candidate for perlecan proteolysis both in silico and in vitro. Purified perlecan showed high sensitivity to MMP-7 digestion even when fully decorated with HS or when presented in native context connected with other BM proteins. In both conditions, MMP-7 produced discrete perlecan fragments corresponding to an origin in immunoglobulin (Ig) repeat region domain IV. While not predicted by in silico analysis, MMP-7 cleaved every subpart of recombinantly generated perlecan domain IV. Other enzymes relevant to PCa that were tested had limited ability to cleave perlecan including prostate specific antigen, hepsin, or fibroblast activation protein α. A long C-terminal portion of perlecan domain IV, Dm IV-3, induced a strong clustering phenotype in the metastatic PCa cell lines, PC-3 and C4-2. MMP-7 digestion of Dm IV-3 reverses the clustering effect into one favoring cell dispersion. In a C4-2 Transwell® invasion assay, perlecan-rich human BM extract that was pre-digested with MMP-7 showed loss of barrier function and permitted a greater level of cell penetration than untreated BM extract. We conclude that enzymatic processing of perlecan in the BM or territorial matrix by MMP-7 as occurs in the invasive tumor microenvironment acts as a molecular switch to alter PCa cell behavior and favor cell dispersion and invasiveness. © 2014 The Authors.


News Article | November 25, 2016
Site: www.newsmaker.com.au

MarketStudyReport.com adds “Biosensors Market Size By Technology (Thermal, Electrochemical, Piezoelectric, Optical), By Application [Medical (Cholesterol, Blood Glucose, Blood Gas Analyzer, Pregnancy Testing, Drug Discovery, Infectious Diseases), Food Toxicity, Bioreactor, Agriculture, Environment], By End-User (Home Healthcare, PoC Testing, Food Industry, Research Labs, Security and Biodefense), Industry Analysis Report, Regional Outlook (U.S., Canada, UK, Germany, China, Japan, Mexico, Brazil, South Africa, Saudi Arabia), Growth Potential, Price Trends, Competitive Market Share & Forecast, 2016  2024” new report to its research database. The report spread across 85 pages with table and figures in it. New discoveries in the field of medical science, government support, rising demand for point of care testing, and the global occurrence of chronic conditions like diabetes along with rapid & accurate detection of such conditions is anticipated to boost the demand for biosensors market over the coming years. The industry growth is expected to further receive a boost owing to the user-friendly as well as cost-effective nature of these biosensor devices. As per the reports of the international diabetes federation, the number of patients suffering from diabetes globally was 366 million in 2011 and the figure is predicted to touch 552 million by 2030.This enormous increase in the number of diabetic patients is expected to benefit the market over the coming years. As per Global Market Insights Inc. report, The biosensors market size worth USD 14.8 billion in 2015, is expected to surpass USD 29 billion by 2024, growing at a CAGR of 8% over the period of 2016-2024. Due to the interdisciplinary approach from various fields such as nanotechnology, medical science, and chemistry, biosensors have found large scale applications in various industries. The use of these biosensor devices in laboratories as well as self-testing coupled with beneficial government policies favoring expansion of genomics as well as proteomics is predicted to further complement the biosensors market growth over the coming years. Many of the IT giants such as Infosys, IBM, and TCS are making heavy investments in the industry and this is predicted to contribute significantly towards the revenue growth of the market over the coming years. Furthermore, growing patient awareness coupled with extended application of biosensors in medical, agriculture, food toxicity, environment, and bioreactor industries will boost the industry growth in near future.  U.S. Biosensors Market Size, By Application, 2012 - 2024 (USD Million) U.S. Biosensors Market Size, By Application, 2012 - 2024 (USD Million) Biosensors find major application in medical segment accounting for nearly 66% of the total revenue of the biosensors market. The largest revenue share can be credited to wide use of biosensors in medical sector. For instance, biosensors help in the diagnosis and monitoring of most of the chronic medical conditions such as cancer, diabetes, etc. Furthermore, the segment which was worth USD 9.8 billion in 2015, is predicted to witness a substantial surge over the coming eight years owing to innovations in optical quantum dots which are used in vaccine development, biopharmaceutical industry, and proteomic analysis. The blood glucose monitoring application held maximum share in medical segment and is projected to contribute over USD 15 billion in terms of revenue by 2024 due to rise in the global occurrence of diabetes. In addition to this, application of biosensors in agriculture segment is predicted to record a CAGR of 11% over the period of 2016-2024. Various technologies used in biosensors industry include optical biosensor, electrochemical biosensor, piezoelectric biosensor, and thermal biosensor technologies. The optical biosensor technology segment is predicted to grow rapidly at a rate of 8.7% over the period of 2016-2024. The electrochemical biosensor technology segment dominated the market by accounting nearly 71% of the overall revenue in 2015, and is expected to surpass USD 21 billion by 2024. This rapidly advancing biosensor technology makes better prediction of the metabolic state of the patient health. Biosensors finds its end-use applications in Biodefense, Home healthcare, Food industry, Point of Care testing, Security, and Research Labs. The end-use application of biosensors in point of care testing segment was worth USD 7 billion in 2015 and is predicted to witness a substantial growth over the coming eight years. Technological innovations leading to new products such as ultrasensitive printable biosensors are predicted to boost the segment growth. The biosensor application in the home healthcare segment is predicted to witness a CAGR of 8.5% over the period of 2016-2024. The Asia Pacific biosensors market is predicted to grow at a CAGR of 11.1% over the period of 2016-2024 due to rising awareness among the patients, growing healthcare access facility, and enhancing healthcare infrastructure. Japan, India, and China are predicted to contribute substantially towards the regional growth owing to rapid economic development and extensive R&D carried out in pharmaceuticals industry coupled with improved healthcare systems. The Latin America biosensors market is forecast to witness a significant surge over the period of 2016-2024. Mexico and Brazil are expected to be the major revenue pockets of the region. The North America market is projected to witness a substantial growth over the period of 2016-2024, owing to the growing occurrence of diabetes & heart diseases, favorable government policies, large number of clinical trials, and advanced healthcare infrastructure facility. The U.S. market is expected to contribute substantially towards the regional growth. Key industry participants include Abbott Laboratories, Johnson & Johnson, LifeScan Inc., Bayer Healthcare, EG &G IC Sensors, Ercon Inc., Biosensor International Ltd, Strategic Diagnostics Inc., and Sysmex Corporation. The market players will try to retain their market position by producing compact and effective biosensors over the coming timeframe. To receive personalized assistance, write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150


Trademark
Sdix Llc and Strategic Diagnostics Inc. | Date: 2012-09-11

Test kits consisting primarily of reagents for scientific use; diagnostic preparations in the nature of antibodies for industrial, scientific and research use; antibody compositions for the discovery and development of biomarkers and creation of biomarker assays for scientific or research use. Hybridoma cell line storage. Custom antibody production and generation; custom manufacture of antibodies for others; antibody purification; antibody fragmentation; custom manufacture of monoclonal and polyclonal antibodies for others. Scientific laboratories performing antibody screening, antibody labeling, antibody testing and hybridoma cell line development; scientific research and development, namely, development of monoclonal and polyclonal antibodies for others; scientific research and development, namely, development of immunoassay testing procedures for others; research and development of therapeutics.


Trademark
Sdix Llc and Strategic Diagnostics Inc. | Date: 2010-12-30

Antibodies for scientific or research use, excluding such uses having application to agriculture. Antibody services, namely, custom antibody production and generation; custom manufacture of antibodies for others, excluding such antibody services having application to agriculture. Scientific research and development, namely, development of antibodies for others, excluding scientific research and development services having application to agriculture.


Gat

Trademark
Sdix Llc and Strategic Diagnostics Inc. | Date: 2011-01-06

Antibodies for scientific or research use, excluding such uses having application to agriculture. Antibody services, namely, custom antibody production and generation; custom manufacture of antibodies for others, excluding such antibody services having application to agriculture. Scientific research and development, namely, development of antibodies for others, excluding scientific research and development services having application to agriculture.


Trademark
Romer Labs Technology Inc. and Strategic Diagnostics Inc. | Date: 2011-09-13

Chemical testing kits for detection of food pathogens; food pathogen enrichment media.


Trademark
Romer Labs Technology Inc. and Strategic Diagnostics Inc. | Date: 2010-03-30

Chemical testing kits for detection of food pathogens; food pathogen enrichment media.


Patent
Strategic Diagnostics Inc. | Date: 2013-03-12

Described herein are methods of screening for compounds that bind to conformational isomers of CD20 polypeptides. Also described are antibodies that bind to conformational isomers of CD20 polypeptides.

Loading Strategic Diagnostics Inc. collaborators
Loading Strategic Diagnostics Inc. collaborators